Literature DB >> 9774223

Effects of nicotine on hydroxyl free radical formation in vitro and on MPTP-induced neurotoxicity in vivo.

B Ferger1, C Spratt, C D Earl, P Teismann, W H Oertel, K Kuschinsky.   

Abstract

Parkinson's disease (PD) is one of the most frequent disorders of the basal ganglia. From epidemiological studies there is a controversial discussion on the question whether tobacco smoking is correlated with a decreased incidence of PD. The present study aimed to elucidate the role of nicotine and its potential neuroprotective effects in a rodent model of PD. These effects may be related to an altered hydroxyl radical formation; this possibility was studied in vitro. Nicotine and alpha-phenyl-N-tert-butyl nitrone (PBN) were examined in a cell-free in vitro Fenton system (Fe3+/EDTA + H2O2) for their radical scavenging properties using the salicylate trapping method. Salicylic acid (0.5 mM) was incubated in the presence and absence of nicotine or PBN and the main products of the reaction of hydroxyl radicals with salicylic acid, namely 2,3- and 2,5-dihydroxybenzoic acid, were immediately determined using HPLC in combination with electrochemical detection. Nicotine and PBN were both able to significantly reduce hydroxyl radical levels at concentrations of 1, 2.5 and 5 mM. Interestingly, at 5 mM nicotine was able to reduce hydroxyl radical levels significantly more than the radical scavenger PBN (5 mM). To investigate the in vivo effects of nicotine, male C57BL/6 mice were used in the MPTP mouse model of PD. Nicotine (0.1 or 0.4 mg/kg s.c.) was administered twice daily for a period of 14 days. On day 8 a single injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 30 mg/kg s.c.) was given as well as an enhanced protocol of nicotine treatment (0.1 or 0.4 mg/kg s.c., 30 min before MPTP and 30, 90, 210, 330, 450, 570 min after MPTP) for a total of seven injections of nicotine. High dosage nicotine treatment significantly increased the MPTP-induced loss of body weight and resulted in a significantly decreased striatal dopamine content and an increased dopamine turnover in comparison with the MPTP-treated controls at day 15. However, the lower dosage of nicotine did not significantly alleviate the MPTP-induced effects, although some parameters showed a slight tendency in this direction. These results demonstrate that in vitro nicotine has radical scavenging properties which might suggest neuroprotective effects. In vivo experiments with nicotine, however, showed that a low dosage of nicotine did not alleviate the MPTP-induced dopamine depletion, but a large dosage even enhanced it.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774223     DOI: 10.1007/pl00005264

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  21 in total

1.  Exosomes as drug delivery vehicles for Parkinson's disease therapy.

Authors:  Matthew J Haney; Natalia L Klyachko; Yuling Zhao; Richa Gupta; Evgeniya G Plotnikova; Zhijian He; Tejash Patel; Aleksandr Piroyan; Marina Sokolsky; Alexander V Kabanov; Elena V Batrakova
Journal:  J Control Release       Date:  2015-03-31       Impact factor: 9.776

Review 2.  Mysterious alpha6-containing nAChRs: function, pharmacology, and pathophysiology.

Authors:  Ke-chun Yang; Guo-zhang Jin; Jie Wu
Journal:  Acta Pharmacol Sin       Date:  2009-06       Impact factor: 6.150

3.  Dose-related neuroprotective effects of chronic nicotine in 6-hydroxydopamine treated rats, and loss of neuroprotection in alpha4 nicotinic receptor subunit knockout mice.

Authors:  R E Ryan; S A Ross; J Drago; R E Loiacono
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

5.  A macrophage-nanozyme delivery system for Parkinson's disease.

Authors:  Elena V Batrakova; Shu Li; Ashley D Reynolds; R Lee Mosley; Tatiana K Bronich; Alexander V Kabanov; Howard E Gendelman
Journal:  Bioconjug Chem       Date:  2007-08-31       Impact factor: 4.774

6.  Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study.

Authors:  S Arpin; E Lagrue; S Bodard; S Chalon; P Castelnau
Journal:  Metab Brain Dis       Date:  2009-09       Impact factor: 3.584

Review 7.  Nicotine and Parkinson's disease: implications for therapy.

Authors:  Maryka Quik; Kathryn O'Leary; Caroline M Tanner
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

Review 8.  Multiple roles for nicotine in Parkinson's disease.

Authors:  Maryka Quik; Luping Z Huang; Neeraja Parameswaran; Tanuja Bordia; Carla Campos; Xiomara A Perez
Journal:  Biochem Pharmacol       Date:  2009-05-09       Impact factor: 5.858

9.  Studies on the interactions of tobacco leaf and tobacco smoke constituents and monoamine oxidase.

Authors:  Kay Castagnoli; Stefanus J Steyn; Geraldine Magnin; Cornelis J Van Der Schyf; Izel Fourie; Ashraf Khalil; Neal Castagnoli
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

10.  Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra.

Authors:  J Andrés Abin-Carriquiry; Ronald McGregor-Armas; Gustavo Costa; Jessika Urbanavicius; Federico Dajas
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.